These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Jan 29, 2018
- "Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" scheduled for 2:15 pm ET on February 1, 2018 in Boston - VANCOUVER, Jan. 29, 2018 /CNW/...
Jan 3, 2018
Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...
Nov 8, 2017
- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK - - On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to...
Nov 7, 2017
- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 - VANCOUVER, Nov. 7, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...
Oct 30, 2017Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy
- SRA737 demonstrates synergy with replication stress-inducing agents - - SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models - - SRA737 potentiated by novel sub-therapeutic...